MNPR — Monopar Therapeutics Share News
0.000.00%
Last trade - 00:00- $487.17m
- $352.87m
U.S. STOCKS ON THE MOVE-Masimo, Icosavax, PayPal
U.S. STOCKS ON THE MOVE-Oatly, Yeti, OpGen
U.S. STOCKS ON THE MOVE-Gap, Levi Strauss, Novavax
Brief: Monopar Announces Successful Advancement Of Camsirubicin Early Stage Study Past Fourth Cohort
Monopar up after positive safety data review for cancer drug trial
Brief: Monopar Therapeutics Files For Offering Of $100 Million Common Stock - SEC Filing
Brief: Monopar Announces Encouraging Clinical Data From Ongoing Camsirubicin Phase 1B Trial
Monopar Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Monopar Therapeutics Reports Third Quarter Results
Monopar Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Avantor, energy sector, Acumen
U.S. STOCKS ON THE MOVE-Nauticus Robotics, Xos, Monopar
Monopar up as enrollment for oral mucositis drug trial begins
Monopar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Monopar Therapeutics Reports Second Quarter 2022 Financial Results
Monopar Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Monopar Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Monopar Therapeutics Reports First Quarter 2022 Financial Results
Monopar Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview